Skip to main content
Premium Trial:

Request an Annual Quote

New Joint Venture to Market Diabetes Test, Develop Biomarkers

NEW YORK (GenomeWeb News) – Toyota Tsusho America and Nippon Kayaku have formed a joint venture that will focus on discovering and selling novel biomarkers and biomarker-based tests for diabetes.
 
The new company, which is called GlycoMark and is located in Winston Salem, NC, and in New York, will sell the GlycoMark diabetes blood test, which the two companies previously commercialized together through a partnership. The GlycoMark test is used to guide management of diabetic patients and for clinical trials on diabetes drugs.
 
The new company initially will focus its efforts on continuing to commercialize the GlycoMark lab test with partner labs in the US, and it also plans to introduce the test in the European Union. The joint venture also is developing a point-of-care and home-test version of the GlycoMark.
 
Toyota Tsusho America is a New York, NY-headquartered company with seven operating divisions, including chemicals, metals, machinery, consumer products and others, and Nippon Kayaku is a fine chemicals manufacturer based in Tokyo.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.